Mariner
SPRY icon

Mariner’s ARS Pharmaceuticals SPRY Stock Holding History

Mariner’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Buy
18,771
+7,535
+67% +$64.8K ﹤0.01% 3241
2026
Q1 		$90.2K Buy
+11,236
New +$108K ﹤0.01% 3348
2025
Q3 		– Sell
-39,713
Closed -$693K – 3748
2025
Q2 		$693K Buy
39,713
+1,740
+5% +$25.1K ﹤0.01% 2071
2025
Q1 		$478K Buy
37,973
+2,065
+6% +$24.8K ﹤0.01% 2240
2024
Q4 		$379K Buy
35,908
+1,972
+6% +$27.6K ﹤0.01% 2414
2024
Q3 		$492K Buy
+33,936
New +$404K ﹤0.01% 2134

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Mariner's SPRY Position: Q2 2026 in Review

Mariner increased its ARS Pharmaceuticals (SPRY) stake by 67% in Q2 2026, buying an estimated $64.8K and bringing the position to 18,771 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #3241.

Mariner first reported a position in SPRY in Q3 2024 and has held it in 6 quarters since. The position peaked at $693K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Mariner held 18,771 shares of ARS Pharmaceuticals worth $150K as of Q2 2026.
  • Mariner bought 7,535 ARS Pharmaceuticals shares in Q2 2026, an estimated $64.8K.
  • ARS Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3241 holding.
  • Mariner first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • Mariner's ARS Pharmaceuticals position peaked at $693K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.